Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TECX
SellSinkerTectonic Therapeutic, Inc. · Healthcare · United States · $696M · Avg Vol: $6M/d
COMPANY DESCRIPTION
Tectonic Therapeutic, Inc. is a biotechnology company focused on discovering and developing G protein-coupled receptor (GPCR)-targeted therapeutics. Leveraging its proprietary GEODe platform, Tectonic aims to create precise and potent modulators for challenging GPCR targets implicated in various diseases. The company operates as a niche, preclinical-stage platform biotech, distinguishing itself through its advanced structural biology and computational approaches to drug discovery.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -2.18 | -2.91 | -6.83 | -4.05 | — | -4.57 | -5.09 | -5.41 | — |
| Shares | 14.7M | 14.7M | 14.9M | 18.7M | +27.2% | 19.5M | — | — | — |
| Debt | 5.8M | 4.3M | 3.3M | 1.3M | -39.6% | 4.4M | — | — | — |
| Equity | -45.7M | -84.6M | 140.8M | 251.3M | 78.5% | — | — | — | — |
| Op CF | -27.6M | -40.7M | -59.1M | -60.1M | — | -72.1M | — | — | — |
| Inv CF | -2.1M | -0.3M | -0.2M | -0.1M | — | — | — | — | — |
| Fin CF | 37.6M | 33.7M | 171.7M | 173.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TECX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TECX | Tectonic Therapeutic, Inc.(you) | $696M | 21 | Sell |
| DRUG | Bright Minds Biosciences Inc. | $714M | 22 | Sell |
| CBIO | Crescent Biopharma, Inc. | $659M | 22 | Sell |
| MPLT | MapLight Therapeutics, Inc. | $584M | 21 | Sell |
| AURA | Aura Biosciences, Inc. | $767M | 23 | Sell |
| STTK | Shattuck Labs, Inc. | $707M | 16 | Strong Sell |
| NVCT | Nuvectis Pharma, Inc. | $775M | 24 | Sell |
| ACHV | Achieve Life Sciences, Inc. | $834M | 19 | Strong Sell |
| FDMT | 4D Molecular Therapeutics, Inc. | $810M | 24 | Sell |
| VSTM | Verastem, Inc. | $654M | 26 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%